{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,21]],"date-time":"2026-10-21T22:30:29Z","timestamp":1792621829717,"version":"4.5.0"},"reference-count":28,"publisher":"Ovid Technologies (Wolters Kluwer Health)","issue":"1","content-domain":{"domain":["lww.com","ovid.com"],"crossmark-restriction":true},"short-container-title":[],"published-print":{"date-parts":[[2021,1]]},"abstract":"<jats:p>Inflammatory myofibroblastic tumor of the uterus (uIMT) is rare. However, it has been increasingly recognized in recent years, largely due to more awareness of its occurrence in the gynecologic tract and the characterization of features that help distinguish it from more common lesions in the differential diagnosis, particularly smooth muscle neoplasms. One of these features is expression of anaplastic lymphoma kinase (ALK, also known as CD246), which has been documented in most uIMTs described in the literature. This review concentrates on the role of ALK testing in the diagnosis and management of uIMT. In terms of immunohistochemistry, an emphasis on antibody selection, sensitivity\/specificity, interpretation and quality control is given. Regarding molecular analysis for <jats:italic toggle=\"yes\">ALK<\/jats:italic> alterations, this review appraises fluorescence <jats:italic toggle=\"yes\">in situ<\/jats:italic> hybridization and RNA sequencing technologies. Lastly, the role of tyrosine kinase inhibitor therapy in patients with uIMT is discussed, highlighting the importance of a correct diagnosis of this entity.<\/jats:p>","DOI":"10.1097\/pgp.0000000000000704","type":"journal-article","created":{"date-parts":[[2020,12,7]],"date-time":"2020-12-07T04:00:41Z","timestamp":1607313641000},"page":"28-31","update-policy":"https:\/\/doi.org\/10.1097\/lww.0000000000001000","source":"Crossref","is-referenced-by-count":26,"title":["ALK Immunohistochemistry and Molecular Analysis in Uterine Inflammatory Myofibroblastic Tumor: Proceedings of the ISGyP Companion Society Session at the 2020 USCAP Annual Meeting"],"prefix":"10.1097","volume":"40","author":[{"given":"Carlos","family":"Parra-Herran","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"276","published-online":{"date-parts":[[2020,12,8]]},"reference":[{"key":"R1-20250802","doi-asserted-by":"crossref","first-page":"1348","DOI":"10.1097\/01.pas.0000172189.02424.91","article-title":"Inflammatory myofibroblastic tumor of the uterus: a clinicopathologic study of 6 cases emphasizing distinction from aggressive mesenchymal tumors","volume":"29","author":"Rabban","year":"2005","journal-title":"Am J Surg Pathol"},{"key":"R2-20250802","doi-asserted-by":"crossref","first-page":"157","DOI":"10.1097\/PAS.0000000000000330","article-title":"Inflammatory myofibroblastic tumor of the uterus: clinical and pathologic review of 10 cases including a subset with aggressive clinical course","volume":"39","author":"Parra-Herran","year":"2015","journal-title":"Am J Surg Pathol"},{"key":"R3-20250802","doi-asserted-by":"crossref","first-page":"1489","DOI":"10.1038\/modpathol.2017.69","article-title":"Inflammatory Myofibroblastic tumor of the uterus: a clinicopathological, immunohistochemical, and molecular analysis of 13 cases highlighting their broad histologic spectrum","volume":"30","author":"Bennett","year":"2017","journal-title":"Mod Pathol"},{"key":"R4-20250802","doi-asserted-by":"crossref","first-page":"623","DOI":"10.5858\/arpa.2011-0341-OA","article-title":"ALK-1 protein expression and ALK gene rearrangements aid in the diagnosis of inflammatory myofibroblastic tumors of the female genital tract","volume":"136","author":"Fuehrer","year":"2012","journal-title":"Arch Pathol Lab Med"},{"key":"R5-20250802","doi-asserted-by":"crossref","first-page":"64","DOI":"10.1097\/PAS.0000000000001083","article-title":"ALK-rearranged tumors are highly enriched in the STUMP subcategory of uterine tumors","volume":"43","author":"Devereaux","year":"2019","journal-title":"Am J Surg Pathol"},{"key":"R6-20250802","doi-asserted-by":"crossref","first-page":"285","DOI":"10.1097\/PAS.0000000000000593","article-title":"Myxoid leiomyosarcoma of the uterus: a clinicopathologic analysis of 30 cases and review of the literature with reappraisal of its distinction from other uterine myxoid mesenchymal neoplasms","volume":"40","author":"Parra-Herran","year":"2016","journal-title":"Am J Surg Pathol"},{"key":"R7-20250802","doi-asserted-by":"crossref","first-page":"66","DOI":"10.1186\/s13045-015-0160-2","article-title":"STUMP un\u201cstumped\u201d: anti-tumor response to anaplastic lymphoma kinase (ALK) inhibitor based targeted therapy in uterine inflammatory myofibroblastic tumor with myxoid features harboring DCTN1-ALK fusion","volume":"8","author":"Subbiah","year":"2015","journal-title":"J Hematol Oncol"},{"key":"R8-20250802","doi-asserted-by":"crossref","first-page":"583","DOI":"10.1007\/s00428-018-2428-8","article-title":"Immunohistochemical and selected genetic reflex testing of all uterine leiomyosarcomas and STUMPs for ALK gene rearrangement may provide an effective screening tool in identifying uterine ALK-rearranged mesenchymal tumors","volume":"473","author":"Pt\u00e1kov\u00e1","year":"2018","journal-title":"Virchows Arch"},{"key":"R9-20250802","doi-asserted-by":"crossref","first-page":"e64821","DOI":"10.1371\/journal.pone.0064821","article-title":"Evaluation of ALK rearrangement in Chinese non-small cell lung cancer using FISH, immunohistochemistry, and real-time quantitative RT- PCR on paraffin-embedded tissues","volume":"8","author":"Zhang","year":"2013","journal-title":"PLoS One"},{"key":"R11-20250802","doi-asserted-by":"crossref","first-page":"492","DOI":"10.1016\/j.lungcan.2015.10.002","article-title":"Comparing four different ALK antibodies with manual immunohistochemistry (IHC) to screen for ALK-rearranged non-small cell lung cancer (NSCLC)","volume":"90","author":"Shen","year":"2015","journal-title":"Lung Cancer"},{"key":"R12-20250802","doi-asserted-by":"crossref","first-page":"345","DOI":"10.1007\/s00428-016-1969-y","article-title":"For staining of ALK protein, the novel D5F3 antibody demonstrates superior overall performance in terms of intensity and extent of staining in comparison to the currently used ALK1 antibody","volume":"469","author":"Taheri","year":"2016","journal-title":"Virchows Arch"},{"key":"R13-20250802","doi-asserted-by":"crossref","first-page":"890","DOI":"10.1067\/S0002-9378(03)00208-4","article-title":"Inflammatory myoblastic tumor of the uterus and interleukin-6","volume":"189","author":"Azuno","year":"2003","journal-title":"Am J Obstet Gynecol"},{"key":"R14-20250802","doi-asserted-by":"crossref","first-page":"625","DOI":"10.1111\/j.1440-1827.2006.02018.x","article-title":"Inflammatory myofibroblastic tumor of the uterus with prominent myxoid change","volume":"56","author":"Shintaku","year":"2006","journal-title":"Pathol Int"},{"key":"R15-20250802","doi-asserted-by":"crossref","first-page":"39","DOI":"10.1016\/j.gynor.2013.07.007","article-title":"Extrauterine inflammatory myofibroblastic tumor: a case report","volume":"6","author":"Kushnir","year":"2013","journal-title":"Gynecol Oncol Case Rep"},{"key":"R16-20250802","doi-asserted-by":"crossref","first-page":"773","DOI":"10.1097\/PAS.0000000000000801","article-title":"Uterine inflammatory myofibroblastic tumors frequently harbor ALK fusions with IGFBP5 and THBS1","volume":"41","author":"Haimes","year":"2017","journal-title":"Am J Surg Pathol"},{"key":"R17-20250802","doi-asserted-by":"crossref","first-page":"3498","DOI":"10.1177\/0300060518780873","article-title":"Anaplastic lymphoma kinase-negative uterine inflammatory myofibroblastic tumor containing the ETV6-NTRK3 fusion gene: a case report","volume":"46","author":"Takahashi","year":"2018","journal-title":"J Int Med Res"},{"key":"R18-20250802","doi-asserted-by":"crossref","first-page":"1433","DOI":"10.1097\/PAS.0000000000000909","article-title":"Inflammatory myofibroblastic tumors of the female genital tract are under-recognized: a low threshold for ALK immunohistochemistry is required","volume":"41","author":"Pickett","year":"2017","journal-title":"Am J Surg Pathol"},{"key":"R19-20250802","doi-asserted-by":"crossref","first-page":"1353","DOI":"10.1097\/PAS.0000000000001120","article-title":"ALK is a specific diagnostic marker for inflammatory myofibroblastic tumor of the uterus","volume":"42","author":"Mohammad","year":"2018","journal-title":"Am J Surg Pathol"},{"key":"R20-20250802","doi-asserted-by":"crossref","first-page":"152","DOI":"10.1097\/PGP.0000000000000588","article-title":"Uterine inflammatory myofibroblastic tumor showing an atypical ALK signal pattern by FISH and DES-ALK fusion by RNA sequencing: a case report","volume":"39","author":"Zarei","year":"2020","journal-title":"Int J Gynecol Pathol"},{"key":"R21-20250802","doi-asserted-by":"crossref","first-page":"1051","DOI":"10.1097\/PAS.0000000000000677","article-title":"ETV6-NTRK3 is expressed in a subset of ALK-negative inflammatory myofibroblastic tumors","volume":"40","author":"Alassiri","year":"2016","journal-title":"Am J Surg Pathol"},{"key":"R22-20250802","doi-asserted-by":"crossref","first-page":"29","DOI":"10.1016\/j.humpath.2019.12.006","article-title":"Uterine inflammatory myofibroblastic tumors in pregnant women with and without involvement of the placenta: a study of 6 cases with identification of a novel TIMP3-RET fusion","volume":"97","author":"Cheek","year":"2020","journal-title":"Hum Pathol"},{"key":"R23-20250802","doi-asserted-by":"crossref","first-page":"1693","DOI":"10.1056\/NEJMoa1006448","article-title":"Anaplastic lymphoma kinase inhibition in non-small-cell lung cancer","volume":"363","author":"Kwak","year":"2010","journal-title":"N Engl J Med"},{"key":"R24-20250802","doi-asserted-by":"crossref","first-page":"1727","DOI":"10.1056\/NEJMoa1007056","article-title":"Crizotinib in ALK-rearranged inflammatory myofibroblastic tumor","volume":"363","author":"Butrynski","year":"2010","journal-title":"N Engl J Med"},{"key":"R25-20250802","doi-asserted-by":"crossref","first-page":"3215","DOI":"10.1200\/JCO.2017.73.4830","article-title":"Targeting ALK with crizotinib in pediatric anaplastic large cell lymphoma and inflammatory myofibroblastic tumor: a Children\u2019s Oncology Group Study","volume":"35","author":"Moss\u00e9","year":"2017","journal-title":"J Clin Oncol"},{"key":"R26-20250802","doi-asserted-by":"crossref","first-page":"115","DOI":"10.6004\/jnccn.2017.7031","article-title":"Inflammatory myofibroblastic tumor driven by novel NUMA1-ALK fusion responds to ALK inhibition","volume":"16","author":"Rao","year":"2018","journal-title":"J Natl Compr Canc Netw"},{"key":"R27-20250802","doi-asserted-by":"crossref","first-page":"1011","DOI":"10.1177\/1078155219879757","article-title":"How long should we continue crizotinib in ALK translocation-positive inflammatory myofibroblastic tumors? Long-term complete response with crizotinib and review of the literature","volume":"26","author":"Alan","year":"2020","journal-title":"J Oncol Pharm Pract"},{"key":"R28-20250802","doi-asserted-by":"crossref","first-page":"607","DOI":"10.1002\/ajh.25043","article-title":"Long-term effects of crizotinib in ALK-positive tumors (excluding NSCLC): a phase 1b open-label study","volume":"93","author":"Gambacorti-Passerini","year":"2018","journal-title":"Am J Hematol"},{"key":"R29-20250802","doi-asserted-by":"crossref","first-page":"431","DOI":"10.1016\/S2213-2600(18)30116-4","article-title":"Crizotinib in patients with advanced, inoperable inflammatory myofibroblastic tumours with and without anaplastic lymphoma kinase gene alterations (European Organisation for Research and Treatment of Cancer 90101 CREATE): a multicentre, single-drug, prospective, non-randomised phase 2 trial","volume":"6","author":"Sch\u00f6ffski","year":"2018","journal-title":"Lancet Respir Med"}],"container-title":["International Journal of Gynecological Pathology"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/journals.lww.com\/10.1097\/PGP.0000000000000704","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2025,8,2]],"date-time":"2025-08-02T19:04:24Z","timestamp":1754161464000},"score":1,"resource":{"primary":{"URL":"https:\/\/journals.lww.com\/10.1097\/PGP.0000000000000704"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2020,12,8]]},"references-count":28,"journal-issue":{"issue":"1","published-print":{"date-parts":[[2021]]}},"URL":"https:\/\/doi.org\/10.1097\/pgp.0000000000000704","relation":{},"ISSN":["0277-1691"],"issn-type":[{"value":"0277-1691","type":"print"}],"subject":[],"published":{"date-parts":[[2020,12,8]]}}}